2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 408
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Ryan Spencer | CEO & Director | 1.25M | N/A | 1978 |
Mr. David F. Novack | President & COO | 925.6k | N/A | 1962 |
Ms. Kelly MacDonald | Senior VP & CFO | 674.27k | N/A | 1984 |
Dr. Robert Janssen | Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs | 789.76k | 35.66k | 1954 |
Mr. Justin Burgess | Principal Accounting Officer & Controller | N/A | N/A | N/A |
Mr. Jeff P. Coon | CHRO and Senior VP of Human Resources & Administration | N/A | N/A | 1963 |
Mr. Paul Cox | VP of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. John Slebir | Senior VP & General Counsel | N/A | N/A | N/A |
Mr. Donn Casale | Chief Commercial Officer | N/A | N/A | N/A |
Dr. Dong Yu | Senior Vice President of Vaccine Research | N/A | N/A | N/A |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Dynavax Technologies Corporation’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 7; Compensation: 3.